Tesofensine 500mcg x30 Capsules
Triple Monoamine Reuptake Inhibitor for Appetite and Weight Research
Tesofensine is a presynaptic serotonin, dopamine, and noradrenaline reuptake inhibitor that achieved the largest Phase 2 weight loss of any non-surgery intervention (~10-12% in 6 months) by suppressing appetite through central monoamine enhancement.
Triple Monoamine Reuptake Inhibitor for Appetite and Weight Research
Tesofensine was originally developed for Parkinson's and Alzheimer's disease when researchers noted profound weight loss in trial participants. It activates central satiety networks by increasing monoamine availability, producing appetite suppression at doses well below those causing cardiovascular effects.
As one of the most studied compounds in the metabolic & fat loss research space, Tesofensine has attracted sustained scientific interest across Weight loss mechanism research, Appetite CNS pathway studies, Monoamine obesity research. Peer-reviewed evidence indicates that ~10-12% weight loss in Phase 2b TIPO trials, which has positioned Tesofensine as a reference standard for researchers exploring weight loss mechanism research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
Tesofensine Documented Benefits: 3 Documented Mechanisms
Appetite Suppression
Enhances serotonin, dopamine, and noradrenaline signaling to suppress central appetite circuits.
Phase 2 Weight Loss
Largest Phase 2 weight loss ever recorded at the time (~10-12% in 24 weeks).
CNS Mechanism
Central monoamine mechanism distinct from GLP-1 pathways for combination research.
How Tesofensine Works: Molecular Mechanism & Pathway
Triple monoamine reuptake inhibitor (SERT/DAT/NET) increasing synaptic serotonin, dopamine, and noradrenaline to enhance central satiety signaling and reduce food intake.
The 3 primary research pathways identified for Tesofensine — Appetite Suppression, Phase 2 Weight Loss, CNS Mechanism — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that triple monoamine mechanism distinct from GLP-1, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, Tesofensine's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
Tesofensine is routinely studied alongside Semaglutide and Retatrutide in metabolic & fat loss-focused compound panels. Researchers investigating weight loss mechanism research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that promising combination with GLP-1R agonists has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All Tesofensine research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- ~10-12% weight loss in Phase 2b TIPO trials
- Triple monoamine mechanism distinct from GLP-1
- Promising combination with GLP-1R agonists
Ideal For
- Weight loss mechanism research
- Appetite CNS pathway studies
- Monoamine obesity research
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on Tesofensine. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
~10-12% weight loss in Phase 2b TIPO trials
Triple monoamine mechanism distinct from GLP-1
Promising combination with GLP-1R agonists
Third-Party Verified Every Batch
Each vial of Tesofensine is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
